期刊文献+

软组织恶性纤维组织细胞瘤的治疗策略和预后分析 被引量:6

Analysis of therapeutic strategies and prognostic factors of malignant fibrous histiocytoma of soft tissue
原文传递
导出
摘要 目的 分析软组织恶性纤维组织细胞瘤的治疗策略及预后相关因素.方法 回顾性分析1999年12月至2010年10月收治的78例软组织恶性纤维组织细胞瘤患者的临床资料,并对性别、年龄、肿瘤部位、肿瘤大小等9项可能影响预后的因素进行统计学分析.结果 60例患者获得随访,随访时间6~131个月,平均35.5个月.l、3、5年总体生存率分别为84.9%、72.9%和56.9%.术后局部复发20例(33.3%),中位局部复发时间为11.5个月(1~72个月).术后转移9例(15.0%),中位转移时间为7个月(1~26个月).单因素分析表明,就诊情况(初治组或复发治疗组)、肿瘤大小和外科边界与生存率有相关性(均P <0.05),外科边界、放疗与局部复发有相关性(P =0.000、0.039),外科边界与远处转移有相关性;多因素分析显示,外科边界是影响生存率(P =0.002,OR=5.753,95%CI1.904~17.386)和局部复发(P=0.000,RR =0.044,95%CI0.010 ~0.188)的独立危险因素.结论 外科边界是影响生存率和局部复发的独立危险因素.采取以手术为主联合放疗的综合治疗,方能减少复发、提高生存率. Objective To assess the therapeutic strategies and risk factors of malignant fibrous histiocytoma of soft tissue.Methods The 78 cases with malignant fibrous histiocytoma of soft tissue treated at Muscular Skeletal Tumor Center of People's Hospital,Peking University from December 1999 and October 2010 were retrospected.Univariate and multivariate analyses were performed to determine the probable risk factors including sex,age,tumor location,tumor size and so on.Results All 60 cases were followed up ranged from 6 to 131 months ( medium 35.5 months).The 1-,3-,5-year overall survival rate was 84.9%,72.9% and 56.9% respectively.Local recurrence rate is 33.3% (20 cases) with a median time of 11.5 months ( 1 to 72 months) and metastatic rate is 15.0% (9 cases) with a median time of 7 months ( 1 to 26 months).Univariate analysis indicated that condition of presentation ( primary case or recurrence case),tumor size and surgical margin were significantly related to survival rate ( all P 〈 0.05,Kaplan-Meier Logrank test),surgical margin and radiotherapy related to local recurrence rate (P value were 0.000 and 0.039 respectively),and surgical margin related to metastatic rate.Multivariate analysis showed that surgical margin was independent risk factors for survival rate ( P =0.002,OR =5.753,95% CI 1.904-17.386) and local recurrence rate (P =0.000,RR =0.044,95% CI 0.010-0.188 ).Conclusions Surgical margin was independent risk factors for survival rate and local recurrence rate.Comprehensive therapy of surgery followed by radiotherapy can improve survival rate,reduce local recurrence rate.
作者 李广学 郭卫
出处 《中华外科杂志》 CAS CSCD 北大核心 2011年第11期974-977,共4页 Chinese Journal of Surgery
关键词 组织细胞瘤 恶性纤维 治疗 预后 Histiocytoma, malignant fibrous Therapy Prognosis
  • 相关文献

参考文献13

  • 1Yamate J,Ogata K,Yuasa T,et al.Adipogenic,osteogenic and myofibrogenic differentiations of a rat malignant fibrous histiocytoma (MFH)-derived cell line,and a relationship of MFH cells with embryonal mesenchymal,perivascular and bone marrow stem cells.Eur J Cancer,2007,43:2747-2756.
  • 2Rao RR,Stice SL.Gene expression profiling of embryonic stem cells leads to greater understanding of pluripotency and early developmental events.Biol Reprod,2004,71:1772-1778.
  • 3Matushansky I,Charytonowicz E,Mills J,et al.MFH classification:differentiating undifferentiated pleomorphic sarcoma in the 21 st Century.Expert Rev Anticancer Ther,2009,9:1135-1144.
  • 4Enneking WF,Spanier SS,Goodman MA.A system for the surgical staging of musculoskeletal sarcoma.1980.Clin Orthop Relat Res,2003 (415):4-18.
  • 5O'Brien JE,Stout AP.Malignant fibrous xanthomas.Cancer,1964,17:1445-1455.
  • 6Enzinger FM.Malignant fibrous histiocytoma 20 years after Stout.Am J Surg Pathol,1986,10 Suppl 1:S43-53.
  • 7Rosenberg AE.Malignant fibrous histiocytoma:past,present,and future.Skeletal Radiol,2003,32:613-618.
  • 8Gutierrez JC,Perez EA,Franceschi D,et al.Outcomes for softtissue sarcoma in 8249 cases from a large state cancer registry.J Surg Res,2007,141:105-114.
  • 9Belal A,Kandil A,Allam A,et al.Malignant fibrous histiocytoma:a retrospective study of 109 cases.Am J Clin Oncol,2002,25:16-22.
  • 10Peiper M,Zurakowski D,Knoefel WT,et al.Malignant fibrous histiocytoma of the extremities and trunk:an institutional review.Surgery,2004,135:59-66.

同被引文献34

  • 1孙小康.周围型肺癌的CT检查及表现[J].中国医学影像技术,2009,25(S1):81-83. 被引量:7
  • 2张如明,卫晓恩.WHO2002年版软组织肿瘤分类初读[J].中国肿瘤临床,2006,33(3):121-125. 被引量:12
  • 3Sakamoto A, Oda Y, Itakura E, et al. Immunoexpression of ultraviolet photoproducts and p53 mutation analysis in atypical fibroxanthoma and superficial malignant fibrous histiocytoma[J]. Mod Pathol, 2001,14(6) : 581-588.
  • 4Bruecks AK, Medlicott SA, Trotter MJ. Atypical fibro- xanthoma with prominent sclerosis[J]. J Cutan Pathol, 2003, 30(5) :336-339.
  • 5Kauffman SL,Stout AP.Histiocytic tumors (fibrous xanthoma and histiocytoma )in children.Cancer, 1961,7 ( 14 ) : 469-482.
  • 6Brine JE, Stout AP.Malignant fibrous xanthomas.Caneer, 1964,13( 17 ) : 1445-1455.
  • 7Fletcher CDM, Unni KK,Merfens F.Pathology and genetics of tumors of soft tissue and bone.Lyon : IARC Press, 2002 : 109-126.
  • 8Fletcher CDM,Gustafson P,Rydholn A,et al.Clinicopathologicre- evaluation of 100 malignant fibrous histiocytomas prognostic relevance of subelassication.J Clin Oncol, 2001,19(12) : 3045-3050.
  • 9Adrien D,Ludger KH,Ingo S,et al.Malignant fibrous histiocytoma- pleomorphic sarcoma,NOS gene expression,histology,and clinical course.A pilot study.Langenbecks Arch Surg, 2010,395 ( 3 ) : 261-275.
  • 10Nedea EA, DeLaney TF. Sarcoma and skin radiation oncology[J]. Hematol Oncol Clin North Am, 2006, 20(2):401-429.

引证文献6

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部